Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 11:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 136 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Interleukin Clear all
Completed Phase 1 Interventional
View directory record Official record
Conditions
HIV Infections, Lymphopenia
Interventions
CYT 107
Drug
Lead sponsor
Cytheris SA
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Miami, Florida • Bethesda, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 17, 2012 · Synced May 21, 2026, 11:37 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Pancreatic Carcinoma
Interventions
HCW9218, Gemcitabine (GEM), Nab-paclitaxel
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Scottsdale, Arizona • Bethesda, Maryland • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced May 21, 2026, 11:37 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Fosaprepitant
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 90 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced May 21, 2026, 11:37 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Neuroblastoma
Interventions
3F8 Monoclonal Antibody Combined with Interleukin-2
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
13 Months and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced May 21, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Childhood Acute Myeloid Leukemia in Remission, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
Interventions
busulfan, etoposide, aldesleukin, peripheral blood stem cell transplantation
Drug · Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced May 21, 2026, 11:37 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies
Interventions
SENTI-202
Biological
Lead sponsor
Senti Biosciences
Industry
Eligibility
18 Years to 74 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2040
U.S. locations
6
States / cities
Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced May 21, 2026, 11:37 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Psoriasis, Aging, Epigenetic Disorder, Inflammation; Skin
Interventions
TILDRAKIZUMAB
Biological
Lead sponsor
Carlos Wambier
Other
Eligibility
35 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced May 21, 2026, 11:37 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Leukemia, Pediatric Cancer
Interventions
Epratuzumab, Fludarabine, Cyclophosphamide, Mesna, Infusion of NK cells, Interleukin-2
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced May 21, 2026, 11:37 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Neuroblastoma
Interventions
SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP, SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2 SKNLP
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced May 21, 2026, 11:37 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Lymphoma
Interventions
aldesleukin, recombinant human stem cell factor
Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Buffalo, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced May 21, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Healthy Participants
Interventions
Tozorakimab, Autoinjector (AI) Device, Accessorised Prefilled Syringe (APFS) Device
Drug · Device
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced May 21, 2026, 11:37 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Hypereosinophilic Syndrome
Interventions
Depemokimab, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
11
States / cities
San Diego, California • Atlanta, Georgia • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced May 21, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Interleukin-2 (aldesleukin).
Drug
Lead sponsor
Scott B. Snapper, MD PHD
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced May 21, 2026, 11:37 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
KSHV Inflammatory Cytokine Syndrome (KICS), Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease
Interventions
Pacritinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 21, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg, Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg
Drug
Lead sponsor
Centocor Research & Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
28
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced May 21, 2026, 11:37 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Proleukin and Dacarbazine
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2026
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced May 21, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Imsidolimab, Placebo
Biological
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
17
States / cities
Birmingham, Alabama • Fountain Valley, California • Northridge, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced May 21, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Imsidolimab, Placebo
Drug · Biological
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
12 Years to 45 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
14
States / cities
Hot Springs, Arkansas • Fountain Valley, California • Sherman Oaks, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced May 21, 2026, 11:37 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Idiopathic Subglottic Stenosis
Interventions
Taltz
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced May 21, 2026, 11:37 PM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
COVID-19 Infection
Interventions
Clazakizumab, Placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced May 21, 2026, 11:37 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Uveitis
Interventions
Daclizumab (Zenapax)
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced May 21, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Oral Lichen Planus
Interventions
Curcuminoids, Placebo
Drug
Lead sponsor
Nita Chainani Wu
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced May 21, 2026, 11:37 PM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Neoplasm, Ovarian, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenocarcinoma Ovary, Serous Adenocarcinoma of Ovary, Serous Adenocarcinoma of Primary Peritoneum, Primary Peritoneal Carcinoma, High Grade Serous Adenocarcinoma
Interventions
AVB-001 (Dose Escalation Phase), AVB-001 (Dose Expansion Phase)
Drug
Lead sponsor
Avenge Bio, Inc
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Bethesda, Maryland • Boston, Massachusetts • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced May 21, 2026, 11:37 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Th17 Helper Immune Cells, Autoimmunity, Salt Intake, Sodium Chloride
Interventions
Low salt diet, Low salt diet + IV normal saline, Liberal salt diet
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced May 21, 2026, 11:37 PM EDT